WALTHAM, Mass., March 29, 2011 /PRNewswire/ — MicroCHIPS, Inc.,
a developer of innovative drug delivery devices and biosensors,
today announced that the U.S. Patent Office and Trademark Office
has granted U.S. Patent No. 7,892,221, Method of Controlled Drug
Delivery from Implant Device. This patent in conjunction with U.S.
Patent No. 7,070,590 provides broad coverage for the design and
fabrication of reservoir-based medical devices used for implantable
drug delivery systems.
MicroCHIPS’ intellectual property originated as patent filings
at the Massachusetts Institute of Technology, by professors and
MicroCHIPS cofounders Robert Langer and Michael Cima, and cofounder
John Santini. These patents are licensed to MicroCHIPS, which has
continued to develop and enhance the reservoir-based technology and
to generate additional intellectual property covering
microreservoirs, controlled release components and systems, and
biosensors. As a result, MicroCHIPS’ current patent portfolio
includes more than 80 patents and more than 50 pending
applications, covering the U.S., Canada, various countries in
Europe and Asia, as well as Australia.
“The granting of this patent provides the fundamental building
blocks for programmable medical drug delivery implants to address
various diseases such as diabetes, osteoporosis, heart disease, and
cancer,” said Robert Langer, ScD, Institute Professor at the David
H. Koch Institute for Integrative Cancer Research at MIT.
MicroCHIPS’ miniaturized systems are adaptable to implants and
catheters as well as on-body delivery systems, external pumps, pens
and infusion systems. Currently, the MicroCHIPS technology is
embodied in the company’s medical implants that are part of a
clinical trial to treat osteoporosis in women. The trial is
evaluating the pharmacokinetics of precise delivery of human
parathyroid hormone (hPTH 1-34) from a programmable, wireless
implanted device.
“This patent and technology portfolio combin
‘/>”/>
